Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature
Abstract Background Gallbladder cancer (GBC) is the most common and aggressive extra hepatic biliary tree cancer (BTC) with dismal outcome. Complete surgical resection is the treatment of choice. Chemotherapy is used for palliation in advanced GBC where surgery is not possible, and the most commonly...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12957-020-01934-4 |
id |
doaj-a02d2103855a45b89e4911c9c5fc88e1 |
---|---|
record_format |
Article |
spelling |
doaj-a02d2103855a45b89e4911c9c5fc88e12020-11-25T02:33:58ZengBMCWorld Journal of Surgical Oncology1477-78192020-07-011811510.1186/s12957-020-01934-4Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literatureKishan Soni0Tarun Kumar1Manoj Pandey2Department of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu UniversityDepartment of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu UniversityDepartment of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu UniversityAbstract Background Gallbladder cancer (GBC) is the most common and aggressive extra hepatic biliary tree cancer (BTC) with dismal outcome. Complete surgical resection is the treatment of choice. Chemotherapy is used for palliation in advanced GBC where surgery is not possible, and the most commonly used agent is gemcitabine in combination with cisplatin or oxaliplatin or with capecitabine regimens. Complete remissions are hardly encountered in these cases; therefore, it is important to combine standard therapies with molecular targeting. Case presentation A 60-year-old woman presented with pain in abdomen and loss of appetite for 1 month, and imaging showed locally advanced gallbladder carcinoma with liver metastasis. After biopsy confirmation, patient was initially started on gemcitabine and oxaliplatin combination followed by gene sequencing, which showed Tp53 (exon 7—c.713 G > A and exon 5—c.376-2A > G) and EGFR (exon 20—T790M) mutation, and erlotinib was added to chemotherapy, after 6 cycles of chemotherapy patient showed a 90% partial radiological response as per RECIST criteria. Conclusion This case reports the possible efficacy of erlotinib in combination with gemcitabine and oxaliplatin in treating an EGFR-mutated GBC with liver metastasis. To our knowledge, this is the first article reporting the response to erlotinib combination therapy with this particular solitary mutation.http://link.springer.com/article/10.1186/s12957-020-01934-4Gallbladder cancerTyrosine kinase inhibitorsGemcitabineErlotinibChemotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kishan Soni Tarun Kumar Manoj Pandey |
spellingShingle |
Kishan Soni Tarun Kumar Manoj Pandey Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature World Journal of Surgical Oncology Gallbladder cancer Tyrosine kinase inhibitors Gemcitabine Erlotinib Chemotherapy |
author_facet |
Kishan Soni Tarun Kumar Manoj Pandey |
author_sort |
Kishan Soni |
title |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature |
title_short |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature |
title_full |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature |
title_fullStr |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature |
title_full_unstemmed |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature |
title_sort |
gallbladder cancer with egfr mutation and its response to gemox with erlotinib: a case report and review of literature |
publisher |
BMC |
series |
World Journal of Surgical Oncology |
issn |
1477-7819 |
publishDate |
2020-07-01 |
description |
Abstract Background Gallbladder cancer (GBC) is the most common and aggressive extra hepatic biliary tree cancer (BTC) with dismal outcome. Complete surgical resection is the treatment of choice. Chemotherapy is used for palliation in advanced GBC where surgery is not possible, and the most commonly used agent is gemcitabine in combination with cisplatin or oxaliplatin or with capecitabine regimens. Complete remissions are hardly encountered in these cases; therefore, it is important to combine standard therapies with molecular targeting. Case presentation A 60-year-old woman presented with pain in abdomen and loss of appetite for 1 month, and imaging showed locally advanced gallbladder carcinoma with liver metastasis. After biopsy confirmation, patient was initially started on gemcitabine and oxaliplatin combination followed by gene sequencing, which showed Tp53 (exon 7—c.713 G > A and exon 5—c.376-2A > G) and EGFR (exon 20—T790M) mutation, and erlotinib was added to chemotherapy, after 6 cycles of chemotherapy patient showed a 90% partial radiological response as per RECIST criteria. Conclusion This case reports the possible efficacy of erlotinib in combination with gemcitabine and oxaliplatin in treating an EGFR-mutated GBC with liver metastasis. To our knowledge, this is the first article reporting the response to erlotinib combination therapy with this particular solitary mutation. |
topic |
Gallbladder cancer Tyrosine kinase inhibitors Gemcitabine Erlotinib Chemotherapy |
url |
http://link.springer.com/article/10.1186/s12957-020-01934-4 |
work_keys_str_mv |
AT kishansoni gallbladdercancerwithegfrmutationanditsresponsetogemoxwitherlotinibacasereportandreviewofliterature AT tarunkumar gallbladdercancerwithegfrmutationanditsresponsetogemoxwitherlotinibacasereportandreviewofliterature AT manojpandey gallbladdercancerwithegfrmutationanditsresponsetogemoxwitherlotinibacasereportandreviewofliterature |
_version_ |
1724811142906249216 |